Once-weekly teriparatide increases bone mineral density in the distal 1/10 radius, but not in the distal 1/3 radius by Nobuo Urushibara et al.
a SpringerOpen Journal
Urushibara et al. SpringerPlus 2014, 3:238
http://www.springerplus.com/content/3/1/238RESEARCH Open AccessOnce-weekly teriparatide increases bone mineral
density in the distal 1/10 radius, but not in the
distal 1/3 radius
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Teriparatide significantly increases bone mineral density (BMD) of the lumbar vertebrae and femur and has a strong
effect in reducing the risk of bone fractures. However, few detailed investigations with dual-energy X-ray absorptiometry
(DXA) of the effects of teriparatide on the radius have been reported; specifically, there are no reports of the use of
once-weekly teriparatide. In this study, the effect of once-weekly teriparatide in increasing BMD was examined in the
distal 1/10 of the radius and the distal 1/3 of the radius using a DXA system for the radius. In addition, the effect of
radius positioning, especially accurate correction of rotation and inclination before and after administration of teriparatide,
was evaluated in an assessment of its efficacy. It was found that when positioning was corrected, a significant increase in
BMD in the distal 1/10 of the radius was observed after 6 months of once-weekly teriparatide. In the distal 1/3 of the
radius, no significant increase of BMD was observed. This suggests that when DXA scans of the radius are analyzed with
appropriate positioning, weekly teriparatide significantly increases BMD in the distal 1/10 of the radius, which is rich in
cancellous bone.
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Teriparatide is a polypeptide consisting of 34 amino acids
(human PTH(1-34)) from the N-terminal of human para-
thyroid hormone (PTH). Teriparatide promotes bone for-
mation by increasing mature osteoblasts. This is achieved
by increasing preosteoblasts through the promotion of
osteoblast precursor cell differentiation and by promoting
preosteoblast differentiation and inhibiting apoptosis in
mature osteoblasts (Isogai et al. 1996) As a result, once-
weekly 56.5 μg teriparatide markedly increases bone min-
eral density (BMD) and shows strong anti-fracture efficacy
(Nakamura et al. 2012). Two teriparatide formulations are
currently used clinically: a teriparatide 56.5 μg once-weekly
formulation (weekly teriparatide) and a teriparatide 20 μg
daily formulation (daily teriparatide).
Dual-energy X-ray absorptiometry (DXA) is a method
of differentiating between the amounts of bone and soft* Correspondence: nukada-3@nifty.ne.jp
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in any medium, provided the original work is ptissue in the human body by irradiation with X-rays of
two different energy levels, measuring the X-ray attenu-
ation at the two respective energies, and calculating the
bone mass per unit area and BMD. BMD using DXA has
become the gold standard for diagnosing osteoporosis
and determining treatment effectiveness because of its
high level of precision and very low level of radiation ex-
posure. Measurement sites are the lumbar vertebrae,
which are rich in cancellous bone, and the femur, which
is rich in cortical bone. Measurements are also possible
at the distal 1/10 of the radius, which is rich in cancel-
lous bone, and the distal 1/3 of the radius, which is rich
in cortical bone.
In studies of the changes in BMD with administration
of teriparatide formulations using DXA, BMD has been
reported to increase significantly in the lumbar vertebrae
(8.1% at 48 weeks and 13.4% at 2 years) and in the prox-
imal femur (3.1% at 72 weeks and 3.3% at 2 years with
both weekly and daily formulations (Fujita et al. 1999;
Miyauchi et al. 2010). With respect to the changes in
BMD in the radius with teriparatide, in contrast, theis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Bone phantom. This is Bone phantom used in this study.
Urushibara et al. SpringerPlus 2014, 3:238 Page 2 of 6
http://www.springerplus.com/content/3/1/238only report is of a 1–2% decrease at 1 year with daily
teriparatide (Neer et al. 2001). There are no reports of
weekly teriparatide. Therefore, the changes in BMD in
the radius with weekly teriparatide were investigated.
When using DXA to investigate serial changes in BMD
due to drugs, it is important that the site measured is the
same before and after the treatment. BMD calculated with
DXA is a number obtained from image measurements,
and discrepancies in the measurement site due to arm po-
sitioning at the time of the measurements are assumed to
affect the measurement results. Therefore, when making
accurate assessments of the efficacy of osteoporosis drugs
based on BMD in a clinical study, it is important to match
sites by establishing evaluation criteria for the target image
data and comparing only image data that meet the evalu-
ation criteria before and after administration of the drug.
In this study, the efficacy of weekly teriparatide was evalu-
ated after investigating the effect on BMD of changes in
arm positioning using a bone phantom.
Subjects and methods
Subjects
The subjects were patients examined at our institution
who had a vertebral compression fracture and were diag-
nosed with primary osteoporosis with BMD of ≤ 70% of
the young adult mean (YAM) in the healthy Japanese
population (Soen et al. 2013). The subjects of the present
analysis were those who had DXA scan images of the ra-
dius taken at the start of weekly teriparatide administration
and after administration for 6 months. Timing of weekly
teriparatide administration was not defined such as morn-
ing or evening. Whether patients had used osteoporosis
drug pretreatment or had complications affecting measure-
ment of BMD was not considered in this study. Analysis of
DXA scans of the radius was done after obtaining written,
informed consent from all subjects. The study was ap-
proved by Nukada memorial hospital subcommittee.
BMD measurement
BMD of the radius was measured using a Dichroma Scan
DCS-600EXV from Hitachi Aloka Medical, Ltd. (Tokyo,
Japan). The distal radius was positioned with reference to
the forearm length from the styloid process of the ulna to
the olecranon. The site located at 1/10 the distance of the
forearm length from the styloid process of the ulna was
taken as the site of the distal 1/10 radius, and the site
located at 1/3 of the distance was taken as the site of the
distal 1/3 radius. In the investigations of BMD in subjects,
the distal radius of the non-dominant arm was taken as the
measurement site.
Effect of arm positioning
When obtaining DXA scans of the radius, rotation and in-
clination of the arm are thought to affect BMD. Therefore,the effect of positioning changes on BMD was examined
using a bone phantom. A PBU-5 whole-body phantom
(Kyoto Kagaku Co., Ltd., Kyoto, Japan) was used as the
bone phantom (Figure 1).
Rotation is a turning movement of the forearm by tor-
sion of the wrist, and inclination is side displacement of
the forearm by placement of the forearm at an angle with
respect to the measurement area. Rotation was taken to
be present when the bone phantom was rotated ±30 de-
grees (pronation: + direction, supination: − direction).
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lel displacement of the proximal portion of the forearm 0–
7 degrees to the side. The effect on BMD of positioning
changes in these respective directions was investigated. In
addition to assessment of BMD at the distal 1/10 and dis-
tal 1/3 radius, the region of interest (ROI) area of the mea-
surement site was calculated.
Correction of BMD changes by inclination at the distal
1/10 radius
The effect of inclination can be avoided by two-
dimensional rotation of the radius DXA scan image
equal to the angle of inclination. This is because inclin-
ation refers to the inclination of the forearm due to
placement of the forearm on an angle with respect to
the measurement area. Specifically, the following manip-
ulations were done at the distal 1/10 radius.
A line extending from the long axis of the radius
within the measurement region was drawn, and this line
was taken as the center line. A straight line was drawn
from the styloid process of the ulna perpendicular to the
measurement region, and this line was taken as the ref-
erence line. The angle obtained from the center line and
reference line with the forearm placed parallel to the
measurement region was taken as the reference angle.
The difference between the reference angle and the
angle obtained from the center line and reference line
with the forearm placed obliquely to the measurement
region was taken to be the inclination angle. Correction
was done by rotating the image by the amount of the in-
clination angle.
Assessment criteria for drug efficacy
To accurately assess drug efficacy from the radius DXA
data obtained from the patients, assessment criteria that
excluded the effects of rotation on BMD before and after
drug administration were set. This is because it is not
possible to accurately compensate for the torsion of the
wrist even with two-dimensional correction of the radius
DXA scan images. A percentage change in the ROI area
of more than 5% was a criterion because it is thought
that the drug efficacy can be detected if the change in
BMD with rotation is kept within 2%, equal to a change
in the ROI area of less than 5%. Therefore, patients with
percentage change in the ROI area of ≥5% were ex-
cluded from the analysis.
Statistical analysis
The data obtained with the radius DXA machine were
analyzed statistically with a paired t-test. P values show
the results of two-sided tests. SPSS statistics 20.0 (IBM
Corp., Armonk, New York, NY, USA) was used for the
statistical analysis.Results
Effect of arm positioning on BMD measurements
The effect of arm positioning on BMD changes was in-
vestigated using a bone phantom (Figure 1). Arm posi-
tioning was evaluated with respect to the effects of two
factors (rotation and inclination).
First, the relationships between rotation and the BMD
measurement value and the ROI area were investigated. The
bone phantom was rotated from -30 to 30 degrees. The
schema of the rotation is shown in Figure 2a in order to get
a better understanding of the method of rotation. The re-
sults of rotation revealed that, as the rotation angle became
larger, BMD increased (Figure 2b), and the ROI area became
smaller (Figure 2c). In addition, assessment of the correl-
ation between the rates of change in BMD and ROI area
with rotation showed a tendency for BMD to increase as the
ROI became smaller (Figure 2d). Changes in BMD with ro-
tation observed at each measurement site were a maximum
of 4% for BMD and 15% for the ROI area in the distal 1/3
radius, and a maximum of 10% for BMD and 20% for the
ROI area in the distal 1/10 radius. Rotation was thus shown
to have a very large effect at both sites.
Next, the relationships between the inclination and BMD
measurement value and the ROI area were investigated.
The bone phantom was inclined from 0 to 7 degrees. The
schema of the inclination is shown in Figure 3a in order to
get a better understanding of the method of inclination. In
the distal 1/3 radius, the inclination angle was found to
have a small effect (~2%) on BMD (Figure 3b) and the ROI
area (Figure 3c), and there were no correlations between in-
clination and BMD and the ROI area (Figure 3d). In the
distal 1/10 radius, BMD increased (Figure 3b), and the ROI
area became smaller (Figure 3c) as the inclination angle be-
came larger. In addition, assessment of the relationship be-
tween the rates of change in BMD and the ROI area with
inclination revealed that BMD increased as the ROI area
became smaller (Figure 3d), confirming a maximum effect
of 10% on BMD and the ROI area.
Finally, the effect of correction on BMD and the ROI
area was investigated. It was found that by correction
with respect to the inclination, the increase in BMD
(Figure 4a) and the decrease in the ROI area (Figure 4b)
produced by the inclination could be reduced to a per-
centage change of less than 1%.Change of BMD by teriparatide treatment
The number of patients before correction was nine. The
number of patients who fulfilled the assessment criteria
after correction was five for the distal 1/10 radius and
seven for the distal 1/3 radius. The patients’ characteristics
are shown in Table 1. There were no significant differences
in age, height, body weight, BMI, or number of prevalent
vertebral fractures between all patients (before correction)
Figure 2 Effect of rotation angle on changes in BMD and area. The schema of the rotation (a) is shown in order to get a better understanding
of the method of rotation. Changes in BMD (b) and area (c) with rotation were detected using the whole-body phantom. The relationship between
BMD and area is shown (d). Open circles indicate values in the distal 1/10 radius, and solid circles indicate values in the distal 1/3 radius. BMD, bone
mineral density.
Figure 3 Effect of inclination angle on changes in BMD and
area. The schema of the inclination (a) is shown in order to get a
better understanding of the method of inclination. Changes in BMD
(b) and area (c) with inclination were detected using the whole-
body phantom. The relationship between BMD and area is shown
(d). Open circles indicate values in the distal 1/10 radius, and solid
circles indicate values in the distal 1/3 radius. BMD, bone
mineral density.
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scan images) (p > 0.05).
Next, weekly teriparatide efficacy was assessed by
comparing radius DXA scan images before the start of
weekly teriparatide and after 6 months. When the above
corrections were not made, no significant increase in
BMD was found in the distal 1/10 radius (p = 0.412) or
the distal 1/3 radius (p = 1.000). When corrections were
made, however, a significant increase in BMD was ob-
served in the distal 1/10 radius (p = 0.001) (Table 2). No
significant increase in BMD was observed in the distal
1/3 radius (p = 0.272) (Table 3).
Discussion
To accurately assess the efficacy of weekly teriparatide in the
distal radius, the effect of changes in arm positioning on
BMD was first examined using a bone phantom. The results
of the investigation of changes in BMD with inclination
showed that the ROI area decreased and BMD increased
with dependence on the inclination angle (Figure 1). The re-
sults of the investigation of changes in BMD with rotation,
which is a three-dimensional movement, showed that,
Figure 4 Effect of the correction for inclination error on arm positioning. Changes in BMD (a) and area (b) before/after correction were
detected. Open triangles indicate values after correction, and solid triangles indicate values before correction in the distal 1/10 radius. BMD, bone
mineral density.
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radius, the ROI area decreased and BMD increased at the
distal 1/10 radius with dependence on the rotation angle
(Figure 2).
Considering these results, it is thought to be important to
define a method to avoid errors in BMD measurement due
to arm positioning changes when assessing the efficacy of
weekly teriparatide using a radius DXA system. The follow-
ing were established as a means of minimizing arm posi-
tioning changes. 1) For inclination, radius DXA scan
images were rotated two-dimensionally in the amount of
the inclined angle. 2) Patients with percentage change in
the ROI area of ≥5% were excluded from the analysis.
The results of the investigation of the BMD-increasing
effect of weekly teriparatide in the six patients who ful-
filled the assessment criteria showed a significant increase
in BMD at the distal 1/10 radius (Table 2). They also
showed that BMD is maintained at the distal 1/3 radius
(Table 3). These results demonstrate that, under properly
established conditions, radius DXA scan images show a
significant increase in BMD at the distal 1/10 radius after
weekly teriparatide administration for 6 months. The rea-




1/10 distal radius 1/3 distal radius
Number of patients 9 5 7
Age (years) 80.4 ± 8.3 80.2 ± 10.2 80.0 ± 8.9
Height (cm) 146.3 ± 8.0 147.0 ± 9.3 146.4 ± 9.0
Body weight (kg) 47.7 ± 7.9 50.9 ± 7.1 48.8 ± 7.1
BMI (kg/m2) 22.4 ± 4.4 23.9 ± 5.3 23.0 ± 4.6
Number of vertebral fractures 3.0 ± 2.4 3.6 ± 2.7 3.6 ± 2.4
BMI, body mass index.the distal 1/10 radius and not at the distal 1/3 radius may
be explained by the difference in the volume of the cancel-
lous bone. The content of cancellous bone is higher at the
distal 1/10 radius than that at the distal 1/3 radius. Be-
cause weekly teriparatide increased cancellous bone rap-
idly, a significant change of BMD was observed only at the
distal 1/10 radius.
The only reports on the efficacy of teriparatide for
BMD of the radius are with daily teriparatide. In an in-
vestigation using DXA, Neer et al. (2001) reported that a
40-µg dose of teriparatide decreased bone mineral dens-
ity at the shaft of the radius by two more percentage
points. Michalska et al. (2012) investigated the efficacy
of daily teriparatide at the distal 1/3 radius using DXA
and reported a significant decrease in BMD of 2–3% at
6 months. Using the results of hr-pQCT, Macdonald
et al. (2011) reported that BMD of the distal radius de-
creased with daily teriparatide. Based on these results,
one could conclude that BMD of the radius decreases
with daily teriparatide.
There is a difference in the direction of the changes in
BMD between these previous findings and the present
results. The detailed mechanism for this difference is un-
clear, but it may be explained in part by metabolic
bone markers. The major difference between weeklyTable 2 Changes from baseline in bone mineral density





0 24 0 24
Distal 1/10 radius
BMD (g/cm2)
0.280 ± 0.076 0.284 ± 0.077 0.306 ± 0.082 0.312 ± 0.081
% increase in BMD 1.17 ± 4.21 1.98 ± 0.87
p value (paired t-test) 0.412 0.001
BMD, bone mineral density.
Table 3 Changes from baseline in bone mineral density





0 24 0 24
Distal 1/3 radius
BMD (g/cm2)
0.421 ± 0.051 0.421 ± 0.054 0.440 ± 0.049 0.444 ± 0.048
% increase in BMD -0.05 ± 2.32 0.98 ± 2.17
p value (paired t-test) 1.000 0.272
BMD, bone mineral density.
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bone resorption marker urine cross-linked N-telopeptide
of type I collagen (NTX). With teriparatide administra-
tion for 6 months, urine NTX showed a percentage
change of -5% from the time administration was started
in the case of weekly teriparatide (Nakamura et al.
2012), but with daily teriparatide, the percentage change
was +50% (McClung et al. 2005). Thus, daily teriparatide
may have caused a decrease in the BMD of radius sites
as a result of strongly renewing bone resorption. This is
similar to a report stating that daily teriparatide in-
creases the porosity of the cortical bone of the radius
using hr-pQCT (Macdonald et al. 2011). Weekly teri-
paratide, in contrast, is thought to increase BMD at the
distal 1/10 radius and maintain the BMD at the distal 1/
3 radius because it inhibits bone resorption.
In any case, there is a limitation that bone metabolic
markers were not measured in this study. Further clin-
ical studies are needed to evaluate the relationship be-
tween change in bone metabolic markers and BMD. To
support the above, a bone structural analysis using hr-
pQCT in patients administered weekly teriparatide may
elucidate the details of the effect of weekly teriparatide
in the radius. Such a study is also needed.Conclusions
A method to avoid irrelevant measurements of BMD
produced by inadequate arm positioning when measur-
ing BMD in the radius was developed, and it was dem-
onstrated that BMD at the distal 1/10 radius was
significantly increased and BMD at the distal 1/3 radius
was maintained after 6 months of once-weekly teripara-
tide treatment. However, further studies with more par-
ticipants are needed to provide clear evidence of the
pharmaceutical effect of once-weekly teriparatide using
the method established in this paper.Competing interests
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